{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:24:43Z","timestamp":1795055083738,"version":"4.10.2"},"reference-count":49,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Cisplatin is used as treatment for various malignant tumors; nevertheless, this anticancer drug frequently causes side effects such as renal damage and hypomagnesemia. Hypomagnesemia has been suggested to cause renal damage, and preventing hypomagnesemia through magnesium supplementation is necessary to continue treatment while maintaining treatment intensity. Although the usefulness of magnesium supplementation has been previously evaluated, problems with the amount of magnesium supplementation and sample size have been identified. This study aimed to examine the usefulness and amount of magnesium supplementation by conducting a meta-analysis of a large number of studies. Methods: This meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. Relevant studies published in PubMed, Scopus, Ichushi, and Cochrane Library databases from inception to 31 December 2025 were selected. The searched text combinations were \u201ccisplatin\u201d and \u201cmagnesium.\u201d Results: Magnesium supplementation showed an inhibitory effect on cisplatin-induced renal injury. The inhibitory effect of magnesium supplementation showed no difference among the three dose groups (&lt;10 mEq, 10\u2013&lt;20 mEq, and \u226520 mEq). Conclusions: Magnesium supplementation is useful for preventing cisplatin-induced nephrotoxicity, irrespective of its dose. The results of this meta-analysis may be clinically helpful in preventing hypomagnesemia-induced nephrotoxicity and continuing treatment.<\/jats:p>","DOI":"10.3390\/jcm15166278","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:47:11Z","timestamp":1786625231000},"page":"6278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Prophylactic Magnesium Therapy for the Prevention of Cisplatin-Induced Renal Injury: A Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Motoki","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Kochi University, Nankoku 783-8505, Japan"},{"name":"Graduate School of Integrated Arts and Sciences, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-4628","authenticated-orcid":false,"given":"Kohei","family":"Jobu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Kochi University, Nankoku 783-8505, Japan"},{"name":"Graduate School of Integrated Arts and Sciences, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Morisawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Odaira","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tokyo Women\u2019s Medical University Hospital, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7111-7746","authenticated-orcid":false,"given":"Takumi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-6507","authenticated-orcid":false,"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital, Kochi University, Nankoku 783-8505, Japan"},{"name":"Graduate School of Integrated Arts and Sciences, Kochi University, Nankoku 783-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sato, K., Watanabe, S., Ohtsubo, A., Shoji, S., Ishikawa, D., Tanaka, T., Nozaki, K., Kondo, R., Okajima, M., and Miura, S. (2016). Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2271-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.2140","article-title":"Acute kidney injury predicts all-cause mortality in patients with cancer","volume":"8","author":"Kang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00686277","article-title":"Cisplatin-induced renal toxicity and toxicity-modulating strategies: A review","volume":"35","author":"Pinzani","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"967826","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: A review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","article-title":"Cisplatin and hypomagnesemia","volume":"25","author":"Lajer","year":"1999","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","article-title":"Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats","volume":"13","author":"Yokoo","year":"2009","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ndt\/gfs268","article-title":"Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury","volume":"28","author":"Alves","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","article-title":"Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: A randomized phase II study","volume":"44","author":"Bodnar","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/bjc.1986.147","article-title":"Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial","volume":"54","author":"Willox","year":"1986","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00000421-199208000-00016","article-title":"Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia: Results of a controlled trial","volume":"15","author":"Martin","year":"1992","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jjco\/hyu004","article-title":"Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: A retrospective study","volume":"44","author":"Yoshida","year":"2014","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/jjco\/hyt128","article-title":"Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study","volume":"43","author":"Hotta","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/jjco\/hyt122","article-title":"Short hydration in chemotherapy containing cisplatin (\u226575 mg\/m2) for patients with lung cancer: A prospective study","volume":"43","author":"Horinouchi","year":"2013","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kidera, Y., Kawakami, H., Sakiyama, T., Okamoto, K., Tanaka, K., Takeda, M., Kaneda, H., Nishina, S.-I., Tsurutani, J., and Fujiwara, K. (2014). Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101902"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1007\/s10147-020-01755-1","article-title":"Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: A prospective study","volume":"25","author":"Hase","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_19","first-page":"3345","article-title":"Preventive effect of magnesium supplementation on cisplatin-induced nephrotoxicity","volume":"30","author":"Miyoshi","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_20","first-page":"481","article-title":"Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity","volume":"25","author":"Saito","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"ref_24","first-page":"562","article-title":"Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer","volume":"4","author":"Muraki","year":"2012","journal-title":"J. Thorac. Dis."},{"key":"ref_25","first-page":"743","article-title":"Magnesium premedication prevents cisplatin-induced nephrotoxicity in patients with esophageal cancer","volume":"40","author":"Hirai","year":"2013","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Oka, T., Kimura, T., Suzumura, T., Yoshimoto, N., Nakai, T., Yamamoto, N., Matsuura, K., Mitsuoka, K., Yoshimura, N., and Kudoh, S. (2014). Magnesium supplementation and high volume hydration reduce renal toxicity caused by cisplatin-based chemotherapy. BMC Pharmacol. Toxicol., 15.","DOI":"10.1186\/2050-6511-15-70"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"767652","DOI":"10.1155\/2014\/767652","article-title":"Comparison of short and continuous hydration regimen in cisplatin chemotherapy","volume":"2014","author":"Ouchi","year":"2014","journal-title":"J. Oncol."},{"key":"ref_28","first-page":"57","article-title":"Feasibility of short hydration in patients with lung cancer treated with cisplatin","volume":"42","author":"Ohhara","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_29","first-page":"2199","article-title":"Nephroprotective effects of magnesium in patients receiving cisplatin","volume":"35","author":"Yamamoto","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_30","first-page":"1379","article-title":"Associations between clinical factors and renal failure due to cisplatin chemotherapy","volume":"42","author":"Yamashita","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/jjco\/hyv203","article-title":"Safety of a short hydration method for cisplatin administration","volume":"46","author":"Sakaida","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_32","first-page":"1873","article-title":"Hydration with magnesium reduces risk for cisplatin-induced nephrotoxicity","volume":"36","author":"Yamamoto","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_33","first-page":"1215","article-title":"Short hydration regimen with magnesium supplementation prevents nephrotoxicity","volume":"25","author":"Yamaguchi","year":"2017","journal-title":"Support. Care Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1111\/jog.13457","article-title":"Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer","volume":"43","author":"Yamamoto","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40463-018-0261-3","article-title":"Renal protective effect of hydration with magnesium in head and neck cancer","volume":"47","author":"Kimura","year":"2018","journal-title":"J. Otolaryngol.-Head Neck Surg."},{"key":"ref_36","first-page":"658","article-title":"Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity","volume":"15","author":"Konishi","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_37","first-page":"13","article-title":"The effect of hydration therapy with and without magnesium sulfate on prevention of cisplatin-induced nephrotoxicity","volume":"11","author":"Ashrafi","year":"2019","journal-title":"Iran. J. Blood Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Minzi, O.M.S., Lyimo, T.E., Furia, F.F., Marealle, A.I., Kilonzi, M., Bwire, G.M., and Malichewe, C. (2020). Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00448-9"},{"key":"ref_39","first-page":"1168","article-title":"Renal function changes with or without magnesium in cisplatin therapy","volume":"56","author":"Hashizume","year":"2020","journal-title":"J. Jpn. Soc. Hosp. Pharm."},{"key":"ref_40","first-page":"1697","article-title":"Risk factors for acute kidney injury in cisplatin chemotherapy","volume":"47","author":"Tagawa","year":"2020","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31083\/ph.2022.11038","article-title":"Correlation between magnesium preloading and nephrotoxicity","volume":"77","author":"Sugisaki","year":"2022","journal-title":"Pharmazie"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10147-025-02780-8","article-title":"Guidance on the Short Hydration Method for Cisplatin Administration","volume":"30","author":"Ninomiya","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","article-title":"Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury","volume":"11","author":"Gupta","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_44","first-page":"54","article-title":"Effect of oral magnesium oxide supplementation on hypomagnesemia","volume":"45","author":"Vakili","year":"2016","journal-title":"Iran. J. Public Health"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Harrach, S., and Ciarimboli, G. (2015). Role of transporters in the distribution of platinum-based drugs. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00085"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","article-title":"Platinum organ toxicity and possible prevention in patients with testicular cancer","volume":"83","author":"Hartmann","year":"1999","journal-title":"Int. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ckj\/sfx007","article-title":"Early detection of acute cisplatin nephrotoxicity","volume":"10","author":"Bunel","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s10147-024-02629-6","article-title":"Relationship between magnesium dosage and preventive effect: Meta-analysis","volume":"29","author":"Okamoto","year":"2024","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:56:09Z","timestamp":1786625769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":49,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166278"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166278","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}